Topical immunosuppressant cancer risk management
Executive Summary
Strategies for cancer risk associated with the use of topical immunosuppressants in children being treated for atopic dermatitis will be discussed at the Feb. 15 meeting of FDA's Pediatric Advisory Committee. The topic was also discussed in 2003 (1"The Pink Sheet" Nov. 10, 2003, p. 41). [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...